Form 4: Director John Roush Acquires LMAT Shares Through Vesting

LeMaitre Vascular Director John Roush reported the acquisition of one common stock share and accrual of dividend equivalent rights through vesting awards.

Summary

• John A. Roush, a Director of LeMaitre Vascular Inc. (LMAT), reported changes in beneficial ownership.
• On December 6, 2025, Roush acquired 1 share of common stock at a price of $0, resulting from the release of dividend equivalent rights.
• Following this transaction, Roush directly owns 2,917 shares of common stock and indirectly owns 181 shares through a spouse.
• On December 4, 2025, Roush acquired various dividend equivalent rights (DERs) totaling 3.7143 units, associated with restricted stock unit (RSU) and performance share unit (PSU) awards granted in 2022, 2023, and 2024.
• On December 6, 2025, 1 dividend equivalent right was released in connection with the vesting of a restricted stock unit award granted on December 6, 2024.
• Each dividend equivalent right is the economic equivalent of one share of the Issuer's common stock and vests proportionately with the underlying awards.
• A Limited Power of Attorney was executed on November 14, 2025, appointing Laurie Churchill, John Pitfield, Bernard Stanford, and Secil Kantarci ONeil as attorneys-in-fact to execute and file SEC forms on behalf of John A. Roush.

Sentiment

Score: 6

Explanation: The filing reports routine insider transactions related to equity compensation, which generally aligns the director's interests with shareholders. The acquisition of shares, even if through vesting, is a positive signal of continued ownership.

Positives

• Director John A. Roush increased his direct beneficial ownership of LeMaitre Vascular Inc. common stock by 1 share.
• The accrual of dividend equivalent rights indicates ongoing equity compensation for the director, aligning interests with shareholders.

Risks

• The Power of Attorney document includes an indemnification clause where John A. Roush agrees to indemnify the attorneys-in-fact and the Company against any demand, damage, loss, cost, or expense arising from false or misleading information provided by Roush.

Future Outlook

This filing does not provide forward-looking statements or guidance regarding the company's future performance.

Industry Context

This Form 4 filing details routine insider transactions related to equity compensation, which is a common practice across industries to align management and director interests with shareholders. It does not provide information on broader industry trends or competitive positioning.

Corporate Governance

Related Party Transactions

• The reported transactions involve the acquisition of common stock and dividend equivalent rights by a director of LeMaitre Vascular Inc. as part of equity compensation, which are standard related-party dealings between an insider and the company.

Stakeholder Impact

• Shareholders: Provides transparency regarding director's beneficial ownership and equity compensation, reinforcing alignment of interests.
• Management/Directors: The Power of Attorney streamlines compliance processes for the director, reducing administrative burden.

Key Dates

Recommendation

This Form 4 details routine insider transactions related to equity compensation vesting. While the director's increased ownership is a minor positive, it does not provide new fundamental information or strategic insights that would warrant a change in investment recommendation. It is a standard compliance filing.

Keywords

LEMAITRE VASCULAR, LMAT, Form 4, insider transaction, director, stock acquisition, dividend equivalent rights, RSU, PSU, beneficial ownership